Monday's Health Winners & Losers
Shares of cancer-drug maker Celgene (CELG) sank after research firm SG Cowen initiated coverage of the stock with a neutral rating.
While Cowen's biotech analyst Phil Nadeau says revenue from the company's Revlimid should reach $2.3 billion in 2010 from $331 million for all of 2006, the drug's success is already priced into the stock, which is "modestly overvalued," he believes. Nadeau says he would look for a pullback before building a position. Shares fell 3.4% to $44.39.
MicroIslet (MII) fell despite an announcement that the company's transplantation studies on diabetic primates reached a six-month milestone. After jumping early in the day, shares were lower by 9 cents, or 5%, to $1.70.
Shares of medical-aesthetics company Syneron (ELOS) were jumping 15.6% to $21.39 after the company reported earnings and reiterated its guidance. Syneron's quarterly revenue reached $27.5 million, up 37% from a year ago and was a record high. Overall, the company earned $8.9 million, or 32 cents a share, including stock-based compensation expenses.Excluding charges, the company earned $11.3 million, or 41 cents a share, in the quarter, up 22% from last year. Analysts were expecting the company to earn 39 cents a share. The company said it was on track to meet its previously announced guidance, which in February called for revenue of between $113 million and $120 million for the full year. Among other health care stocks on the move were pharmaceutical company NitroMed (NTMD), which was gaining 14.1% to $2.91, drug developer Taro Pharmaceutical Industries (TARO), up 7.7% to $12.81, biotech ICAgen (ICGN), higher by 7.1% to $1.20, and Spectrum Pharmaceuticals (SPPI), up 3.4% to $3.68. Accentia Biopharmaceuticals (ABPI) was down 1.6% to $3.03, Ivax Diagnostics (IVD) fell 8.2% to $1.56, Oscient Pharmaceuticals (OSCI) was down 6% to $1.25, Nyer Medical Group (NYER) lost 9.7% to $2.80, Alpharma (ALO) was down 6.6% to $21.65, and Rigel Pharmaceuticals (RIGL) was losing 3.8% to $9.20.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV